The effects of the composition of PBPC grafts from matched related donors (MRDs) and matched unrelated donors (MUDs) have not been compared. In a single-center study, the compositions of 55 MRD PBPC grafts and 33 MUD grafts were studied for their effect on the rate of engraftment in patients who had evidence of donor cell engraftment on day þ 28. The MUD grafts came more frequently from young male donors and contained more CD34 þ cells but similar numbers of colony-forming units granulocyte-macrophage (CFU-GM) and burst forming units-erythroid. The recovery of neutrophils to 4500/mm 3 was equally fast in both groups, but recovery of platelets to 420 000/mm 3 was significantly delayed in the MUD group (Po0.001). The MUD group also required more transfusions of platelets and red cells. Patients receiving grafts containing low numbers of CFU-GM had markedly delayed platelet recovery. The patients with the slowest engraftment tended to have prolonged transportation times. Storage experiments suggested a major loss of viable CD34 þ cells and CFU-GM when undiluted PBPC products are stored at room temperature. The data suggest that a fraction of the MUD grafts suffer during transportation. In vitro proliferation assays should be part of the validation and auditing of transportation of MUD grafts.
Introduction
PBPCs mobilized with filgrastim (Neupogen; Amgen, Thousand Oaks, CA, USA) have become an increasingly frequent source of stem cells for allogeneic transplantation. Over the last decade, PBPCs have replaced BM as the preferred stem cell source in many programs. 1, 2 Studies to compare the results of SCT with PBPCs and BM, with special attention to engraftment kinetics, GVHD and risk of recurrence of the underlying malignant disease have been performed for matched related donor (MRD) transplants 3, 4 and are ongoing for matched unrelated donor (MUD) transplants. 5 The composition of the stem cell graft has a major influence on the engraftment kinetics after autologous PBPC transplantation. [6] [7] [8] Thus, increasing the dose of PBPCs results in faster hematologic recovery with lower resource utilization. 7, 8 Although the minimum dose of PBPCs for autologous recovery, expressed as dose of CD34 þ cells, is as low as 1-2 Â 10 6 /kg, 9 doses of at least 5 Â 10 6 /kg have been shown to result in faster recovery of, in particular, the platelet count. 7, 8 Indeed, highly significant correlations exist between the CD34 þ cell dose and the number of days until absolute granulocyte count (AGC) 4500/mm 3 and days until unsupported platelet count 420 000/mm 3 , respectively. [6] [7] [8] [9] As many patients receiving relatively small doses of CD34 þ cells show adequate engraftment, the importance of the composition of the PBPC allograft has received only limited attention. [10] [11] [12] [13] The effect of the composition of the PBPC grafts from MRDs and from MUDs on hematologic recovery of the patents was studied, with particular attention to the differences between MRD and MUD grafts.
Materials and methods

Patients
All recipients of allogeneic PBPC transplantation between 2002 and 2007 were included in this study if they had full or partial hematologic chimerism as documented with variable number tandem repeats (VNTR) technology by day þ 28 and had received PBPC grafts with known infused doses of CD34 þ cells and colony-forming units granulocyte-macrophage (CFU-GM). Two patients who had major complications potentially influencing engraftment (veno-occlusive disease of the liver and multiorgan failure) were excluded. One patient who had not shown any signs of engraftment by day þ 40 was also excluded because immunological rejection as the cause of graft failure could not be excluded. This study had been approved by the Institutional Review Board of St Francis Hospital and Health Centers.
PBSC grafts
All donors, related and unrelated, underwent 'mobilization' with filgrastim (Neupogen; Amgen) at 10 mg/kg per day for four consecutive days before the start of PBPC collection. The collection was done with a continuous flow blood cell separator as per institutional guidelines of the donor center. For related donors, the COBE Spectra (Gambro BCT, Lakewood, CO, USA) was used and 3 Â donor blood volumes were processed. The grafts were transported to the stem cell laboratory for processing and were then immediately transferred to the transplant floor and infused over 2-3 h. Grafts were minimally manipulated with only plasma reduction for ABO incompatibility required; plasma was replaced with Plasma-Lyte A (Baxter Healthcare, Deerfield, IL, USA). All PBPC grafts from MUDs were facilitated through the National Marrow Donor Program (NMDP, Minneapolis, MN, USA). The concentration of WBCs in these PBPC products during transport was 244.5 ± 75.6/mm 3 (mean ± s.d.). For these unrelated donors, the interval in hours between the completion of the final collection and the arrival at the bedside was calculated. For MRD, this interval was always less than 4 h.
In the stem cell laboratory, samples were obtained for determination of total WBC count, differential viability by Trypan blue exclusion, bacterial and fungal cultures, CD34 þ cells, CD3 þ cells, CFU-GM and BFU-e (burst forming units-erythroid). The CD34 þ and CD3 þ cells were assessed with a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA) as described. 8 The ISHAGE protocol for CD34 þ enumeration was used. For the CD3 þ cell analysis, anti-CD3 antibody FITC (clone SK7) was used in combination with CD45-FITC and CD14-PE Leuco gate (Becton Dickinson).
The CFU-GM/BFU-e assays were performed as described. 8 Aliquots of the methylcellulose cellular mixture were plated into two petri dishes with a final cell concentration in each plate of 10
5
. After a 14-day incubation, the petri dishes were counted in situ with an inverted microscope; the results of the two dishes were averaged. Colony forming unit granulocyte-erythroidmonocyte-macrophage was scored as both CFU-GM and BFU-e.
To study the influence of temperature and concentration on the composition of the PBPC products over time, samples of freshly collected PBPCs from MRDs were incubated for up to 96 h. Parallel samples were incubated at 4 1C and at room temperature, both at the original concentration and diluted 1:10 with autologous plasma. Samples were taken daily for WBC count, Trypan blue viability (Trypan blue 0.4%; Sigma, St Louis, MO, USA), 7-AAD (7-amino actinomycin D; Becton Dickinson) viability, CD34 concentration, CFU-GM and BFU-e. The percentage of viable CD34 þ cells were obtained from twocolor fluorescence studies for CD34 and 7-AAD.
Preparative regimens
Patients who underwent allogeneic PBPC transplants after a fully myeloablative preparative regimen were treated with intravenous CY at 2100 mg/m 2 /day for two consecutive days preceded by either BU at 3.2 mg/kg/day intravenously for 4 days, or by TBI at 200 cGy twice a day for six doses (total dose 1200 cGy). Patients who underwent transplant after a reduced-toxicity preparative regimen were treated with intravenous fludarabine at 30 mg/m 2 /day for five consecutive days, followed by a single intravenous dose of melphalan at 140 mg/m 2 .
Prevention of GVHD
All patients received CYA starting on day À1; the aim was to have trough levels of 200-250 ng/ml. The patients with a reduced-toxicity preparative regimen received alemtuzumab (Campath; Berlex, Seattle, WA, USA) at 20 mg/day intravenously for five consecutive days.
14 Patients who underwent a myeloablative regimen received either thymoglobulin (Genzyme, Cambridge, MA, USA) at 2 mg/kg/day for 3 days (days À3, À2 and À1) or Cellcept (mycophenolate mofetil; Roche Pharmaceuticals, Nutley, NJ, USA) at 500 mg orally four times a day, starting on the day of stem cell infusion.
Supportive care
Patients did not routinely receive hematopoietic growth factor support after transplant. If the AGC on day þ 15 was still o100/mm 3 , filgrastim was started at a dose of 5 mg/kg/day subcutaneously. Platelet support consisted of transfusion of single-donor apheresis platelets to keep the platelet count above 10 000/mm 3 , and red cell transfusions were used to keep the hemoglobin level above 8.0 g/100 ml.
Engraftment
Hematologic recovery was assessed by a number of parameters that are part of the center's quality management program. These factors include determining the day after PBPC infusion when the AGC exceeds 500/mm 3 for the first of three consecutive days, and the day when the platelet count exceeds 20 000/mm 3 without the need for further platelet transfusions. The numbers of red blood cell units and platelet transfusions required during the transplant episode were also scored.
Results
Patients
A total of 88 patients were available for study. This group consisted of 55 patients who received related PBPC transplants from MRDs and 33 patients who received PBPC grafts from MUDs. The clinical features of the two groups of patients are listed in Table 1 . The groups were not significantly different for gender and age, even though the MUD patients tended to be younger. The diagnoses for which the transplants were performed and the preparative regimens did not differ significantly between the two groups either. The regimens to prevent acute GVHD, on the other hand, had significantly different distributions between the two populations of patients: MRD patients received mycophenolate mofetil more frequently, whereas nearly all MUD patients underwent some type of in vivo T-cell depletion with alemtuzumab or thymoglobulin.
Donors
Data on the PBPC donors and on the composition of the stem cell grafts are listed in Table 2 . MUDs were significantly younger than MRDs and more frequently men. No difference was found between MRD and MUD grafts as far as ABO incompatibility with the recipient is concerned. The MUD patients received a larger dose of CD34 þ cells, but the doses of CD3 þ cells, CFU-GM and BFU-e were not significantly different between the two groups. The larger dose of CD34 þ cells in the MUD grafts may be partly explained by donor age. 10 A significant correlation existed between the age of the donor and the CD34 concentration in the PBPC graft (P ¼ 0.04). The Trypan blue viability of the MRD products was always X99%. The Trypan blue viability of the MUD products on arrival varied between 87.4 and 99.5% with a median of 98.5% and a mean of 97.2% (s.d. 2.3%).
Engraftment
By definition, all patients engrafted, as those with early death or rejection (no evidence of donor cells by VNTR on day þ 28) were excluded from the study. An AGC 4500/ mm 3 was reached between 8 and 30 days after PBPC infusion with a median of 15 days. An unsupported platelet count of 420 000/mm 3 was reached after 7-117 days with a median of 12 days. When engraftment of neutrophils and platelets was compared, the recovery of platelets was significantly faster than the recovery of neutrophils with a median difference of 2 days (Po0.0001). The recovery of neutrophils and platelets was closely correlated (r ¼ 0.47; Po0.0001), but the correlation between days to AGC 4500/mm 3 and to platelets 420 000/mm 3 was better for MRD grafts (r ¼ 0.57; Po0.0001) than for MUD grafts (r ¼ 0.10; P ¼ 0.09). Table 3 compares the engraftment parameters of the MRD and MUD groups. Although the days to AGC 4500/mm 3 were similar for the two groups (Figure 1 ), the platelet recovery was significantly faster for the MRD group (Figure 2) . The slower platelet recovery of the MUD patients appears to be caused by a 'tail' of the curve representing about 25% of the patients (Figure 2) . The transfusion requirements for the MUD group were also much higher, both for red cell units and for platelet transfusions.
Factors predicting engraftment
As the delayed recovery of platelets could have been caused by differences in patient populations, it was important to study the effect of clinical features on the time to engraftment. As far as could be determined, no clinical features predicted engraftment reliably. The preparative regimen had little effect on engraftment. Patients who received the reduced-toxicity preparative regimen (fludarabine and melphalan) had slightly slower recovery of neutrophils (median 15 days, range 11-30 days) than patients who received BU/CY or TBI/CY preparative regimens (median 14 days, range 8-22 days) (P ¼ 0.02), but the recovery of platelets was identical (P ¼ 0.99). Similarly, the choice of GVHD prophylaxis between thymoglobulin and mycophenolate mofetil did not have an effect on the recovery of either neutrophils (P ¼ 0.91) or platelets (P ¼ 0.64).
The composition of the PBPC grafts was studied for its prediction of engraftment. As shown in Table 4 , the CD34 þ and CD3 þ cell doses did not significantly correlate with the days to AGC 4500/mm 3 or to platelets 420 000/ mm 3 . On the other hand, the dose of CFU-GM was predictive for the rate of platelet recovery. The dose of CFU-GM ( Â 10 4 /kg) was correlated with platelet recovery with a Spearman's rank correlation coefficient of À0.31 (P ¼ 0.0035). This correlation between CFU-GM dose and days to platelets 420 000/mm 3 was stronger for MUDs (r ¼ À0.45) than for MRDs (r ¼ À0.23). The CFU-GM dose did not correlate with neutrophil recovery. As anticipated, the doses of CD34 þ cells and CFU-GM showed a significant correlation (r ¼ 0.41; P-value o0.0001).
The number of hours from completion of the last PBPC collection until the start of the infusion into the patient was calculated. For MRD grafts, the interval was always less than 4 h and was not analyzed further. For MUD grafts, the interval varied between 8 and 47 h, with a median of 29.5 h. In the recipients of these MUD grafts, no statistically significant correlation was found between the delay of infusion and the rate of engraftment, as determined by days to AGC 4500/mm 3 (r ¼ 0.21; P ¼ 0.23), or to platelets 420 000/mm 3 (r ¼ 0.16; P ¼ 0.38).
Delayed engraftment
Although engraftment of PBPC grafts from MRDs was reasonably homogeneous, the time to engraftment after Platelet recovery after unrelated transplants J Jansen et al grafts from MUDs was more erratic. In particular, the recovery of platelets was more unpredictable, and the correlation between the rates of neutrophil and platelet recovery after MUD transplant was not significant (see above). In addition, the CFU-GM dose of the PBPC product was found to predict the recovery of platelets, in particular in recipients of MUD transplants (see above). Therefore, an analysis of patients with very low CFU-GM doses was undertaken. The four patients who received a CFU-GM dose of p16.0 Â 10 4 /kg were all MUD graft recipients, which indicated that more grafts from MUD had very low CFU-GM contents than PBPC grafts from MRD (P ¼ 0.02). These four patients reached AGC 4500/ mm 3 after a median of 17 days (range 15-30 days), and platelets 420 000/mm 3 after a median of 29 days (range 14-90 days). The interval between completion of collection and start of infusion for these four patients had a median of 36.5 h (range 21-44 h). Interestingly, the two PBPC grafts from MRD, which had very low CFU-GM doses (16.2 and 16.9 Â 10 4 /kg), had platelet recovery by day 11.
In vitro storage experiments Samples of fresh PBPC products from three consecutive MRDs were stored for 4 days at 4 1C or at room temperature, both undiluted and diluted 1:10 with autologous plasma. These four parallel samples were tested daily for viability and for in vitro growth (CFU-GM and BFU-e). As shown in Table 5 , the samples stored at 4 1C had excellent recovery both for viability and in vitro growth potential. The diluted samples stored at 4 1C appeared to have the best survival with Trypan blue viability of 89%, viability of CD34 þ cells at 86% and growth of CFU-GM of 57% of the original product even after 96 h of storage. Undiluted samples stored at room temperature, on the other hand, had poor survival: although Trypan blue viability at 24 h was still at 86%, the viability of CD34 þ cells was already down to 74% and that of CFU-GM growth to 21% of the original product. After 72 h, Trypan blue viability was down to 64%, but CD34 þ viability and CFU-GM growth were far worse with 7% and 6% of the original product, respectively. The CFU-GM survival for the diluted samples stored at 4 1C was superior to the undiluted samples stored at room temperature at all time points (P-values between 0.03 and 0.003). The 10-fold dilution of samples stored at room temperature resulted in survival better than the undiluted sample at room temperature, but worse than the samples stored at 4 1C. Samples stored in culture tubes and samples stored in gaspermeable bags produced the same results, suggesting that lack of oxygen was not responsible for the poor survival of samples at room temperature.
Discussion
This single-center study of PBPC allografts did not show a significant correlation between the dose of CD34 þ cells and hematologic recovery as defined by days to AGC 4500/ mm 3 and/or platelets 420 000/mm 3 . This observation confirms earlier studies that suggested little correlation between CD34
þ cell dose and engraftment in allogeneic grafts, except for very small CD34 doses. [11] [12] [13] On the other hand, the current study suggests that the CFU-GM dose is correlated with platelet recovery, in particular for MUD transplants. The results of this allograft study are quite different from the results of autologous PBPC transplants, where a close correlation exists between the CD34 þ dose and the rate of engraftment of both neutrophils and platelets. [6] [7] [8] For autologous PBPC grafts, the dose of CFU-GM did not independently contribute to the prediction of engraftment after transplant, but had effect only through its correlation with the CD34 dose. 8 Hematologic recovery of neutrophils was similar after PBPC transplants from MUDs and from MRDs. The recovery of platelets, however, was clearly slower after transplants from MUD than from MRD. The difference in median days to platelets 420 000/mm 3 was only 1 day, but the recovery curves were statistically highly significantly different (Figure 2 ; Po0.001). Similarly, the number of platelet transfusions required was significantly different between the two groups, as was the number of red cell units required, with MUD patients requiring more transfusion support than MRD patients.
The delayed platelet recovery after MUD allografts may have a variety of causes. The MRD and MUD groups were reasonably balanced for age, gender, indication for transplant and preparative regimen. Significant differences between the two groups existed for GVHD prophylaxis. Even though mycophenolate mofetil may well cause myelosuppression, in this study the different regimens to prevent acute GVHD did not have significant influence on the hematologic recovery of the patients, supporting earlier Table 5 Effect of temperature and cell concentration on survival of PBPC over time (n ¼ 3) studies suggesting that CYA/mycophenolate mofetil prophylaxis results in faster engraftment than prophylaxis with CYA/methotrezate. 15 MUD transplants, in general, are associated with more toxicity and morbidity than MRD transplants. Typically, though, these complications arise after engraftment has occurred. By excluding the small number of patients with early death or serious organ failure during the first 28 days after transplant from this analysis, we attempted to limit the measured hematologic effects associated with the potentially higher morbidity of MUD patients.
An alternative explanation would be qualitative or quantitative differences in the PBPC products. MRD and MUD products had similar numbers of CFU-GM and CD3 þ cells, whereas the MUD products had higher CD34 þ doses. The MUD products were also derived from younger, and preferably male, donors. It would be hard to explain why a higher dose of CD34 þ cells from younger male donors would lead to delayed hematologic recovery. More likely, the delayed engraftment after MUD transplant was associated with factors influencing the PBPC products between the time of collection from the donor and infusion into the patient. The number of hours between the time of collection from the donor and infusion after MUD transplants was not significantly correlated with the rate of engraftment. Nevertheless, the four patients with a very low CFU-GM dose did have long transport times (median of 36.5 h) and experienced longer times to engraftment. An additional MUD patient transplanted by our program had very low CFU-GM growth (0.6 Â 10 4 /kg) and did not engraft at all. This patient was not included in this study, as at no time could evidence of engraftment be detected by VNTR technology. In a study of MUD BM grafts, intervals of up to 36 h between harvest and infusion had little or no effect on the recovery of platelets. 16 It is conceivable that PBPC grafts with their much higher cell concentrations are more susceptible to damage during prolonged storage and exposure to various conditions during transport than BM grafts. 16 The in vitro storage data presented here support the concept that products with high cell concentration survive more poorly, in particular at room temperature.
During these in vitro experiments, it became clear that overall viability determined by Trypan blue exclusion is far less sensitive than viability of CD34 þ cells using the 7-AAD methodology. Nevertheless, when PBPCs are kept at room temperature for 24 h, the Trypan blue viability already starts to decrease. The decrease in CD34 þ cell viability is more pronounced than in Trypan blue viability at all points in time, and CFU-GM survive even more poorly. On the other hand, when PBPC products are kept at 4 1C viability, as determined by Trypan blue exclusion, CD34
þ cell viability and CFU-GM are well maintained, in particular when the PBPCs were diluted 10-fold with autologous plasma. The survival of CFU-GM correlated well with the viability of CD34 þ cells, but may well be even more sensitive to damage than the 7-AAD viability of CD34 þ cells. For practical reasons, engraftment expectations have been based largely on total CD34 þ cell engrafting doses. Obviously, CFU-GM cannot be used for prospective determination of progenitor cell concentrations. CFU-GM techniques are also more laborious and prone to inter-laboratory differences. 2 These data further suggest that, in a fraction of MUD transplants, the PBPC product is likely 'damaged' relative to in vitro growth characteristics during the interval between collection and infusion. Additional support for this hypothesis derives from the results of second donations by two unrelated donors for patients at our center who had poor engraftment or no engraftment at all after their initial PBPC infusion. Typically, healthy donors produce similar doses of CD34 þ cells during subsequent collection attempts. 17, 18 In contrast to the first products that had adequate numbers of CD34 þ cells ( /kg, respectively). These second infusions resulted in prompt hematologic recovery (within 14 days). If our hypothesis is correct that damage may occur during the transport of PBPC products from MUDs, quality control measures become increasingly important. Possible factors of importance include duration of transport, temperature and cell concentration during transport, and handling of the product by the courier. The analysis of a larger number of patients is needed to better understand our observations for MUD products. Some types of proliferation assays would appear to be important for future validation and auditing processes.
